13FGuru
Sign in with Google Sign in with Discord

NYSE · Health Care

TEVA PHARMACEUTICAL INDS LTD TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Sources StockAnalysis company profile stockanalysis.com
Biotechnology: Pharmaceutical Preparations

Company profile

Business mix

  • It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.
  • The company also focuses on the central nervous system (CNS), respiratory, and oncology areas.
  • The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma.
  • The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within drug manufacturers - specialty & generic?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 3 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 25.53 FCF 2.94% Buyback -2.93%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Glenview Capital Management Larry Robbins 5.0% $200.6M 2026-03-31
Bridgewater Associates Ray Dalio 0.2% $34.0M 2026-03-31
Duquesne Family Office Stanley Druckenmiller 2.1% $71,604 2026-03-31

Recent trading changes over the last 4 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 1 Last 4 13F filing periods
Net reducers 2 Last 4 13F filing periods
Unchanged holders 1 Share count unchanged
Increase amount $11.3M Estimated from net added shares
Reduction amount $244.9M Estimated from net reduced shares
Net share change / base shares -66.6% -20,246,573 / 30,412,484
Duquesne Family Office Stanley Druckenmiller 4 filing periods
13F 2025-06-30 Filed 2025-08-15
Minor increase Shares 7.3% 13F value change +$38,937
13F 2025-09-30 Filed 2025-11-14
Minor increase Shares 3.9% 13F value change +$67,558
13F 2025-12-31 Filed 2026-02-17
Major reduction Shares -64.6% 13F value change -$151,842
13F 2026-03-31 Filed 2026-05-15
Major reduction Shares -59.5% 13F value change -$111,751
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 14,879,750 Last 4 periods -12,502,465 (-84.0%) Total shares 2,377,285 Value $71,604
Bridgewater Associates Ray Dalio 1 filing periods
13F 2026-03-31 Filed 2026-05-15
Major increase Shares 49.6% 13F value change +$10.5M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 754,093 Last 4 periods +374,313 (+49.6%) Total shares 1,128,406 Value $34.0M
Glenview Capital Management Larry Robbins 4 filing periods
13F 2025-06-30 Filed 2025-08-14
Minor increase Shares 7.1% 13F value change +$38.1M
13F 2025-09-30 Filed 2025-11-14
Minor increase Shares 5.5% 13F value change +$72.0M
13F 2025-12-31 Filed 2026-02-17
Minor increase Shares 0.2% 13F value change +$184.6M
13F 2026-03-31 Filed 2026-05-15
Major reduction Shares -60.2% 13F value change -$321.2M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 14,778,641 Last 4 periods -8,118,421 (-54.9%) Total shares 6,660,220 Value $200.6M
Viking Global Investors Andreas Halvorsen 4 filing periods
13F 2025-03-31 Filed 2025-05-15
New Shares - 13F value change +$155.6M
13F 2025-06-30 Filed 2025-08-14
Major increase Shares 15.4% 13F value change +$40.2M
13F 2025-09-30 Filed 2025-11-14
Major reduction Shares -78.3% 13F value change -$144.6M
13F 2025-12-31 Filed 2026-02-17
Sold out Shares -100.0% 13F value change -$51.1M
Settlement As of 13F 2025-12-31 · Filed 2026-02-17
Base shares 0 Last 4 periods +0 (New) Total shares 0 Value $0

Recent mentions

No public mentions.